Recognising RSV infection in adults: The role of recently-developed vaccines
Article Sidebar
Main Article Content
Abstract
-
Downloads
Article Details
Issue
Section
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under Attribution-Non Commercial International Creative Commons Attribution (CC-BY-NC 4.0) License. Under this license, authors agree to make articles available to users, without permission or fees, for any lawful, non-commercial purpose. Users may read, copy, or re-use published content as long as the author and original place of publication are properly cited.
Exceptions to this license model is allowed for UKRI and research funded by organisations requiring that research be published open-access without embargo, under a CC-BY licence. As per the journals archiving policy, authors are permitted to self-archive the author-accepted manuscript (AAM) in a repository.
How to Cite
References
1. Mkhize TL, Zurba Feldman C, Anderson R. RSV: an overview of infection in adults. Pneumonia 2025;17:15. https://doi.org/10.1186/s41479-025-00165-z
2. Doty B, Ghaswalla P, Bohn RL, et al. Incidence of RSV in adults: a comprehensive review of observational studies and critical gaps in information. J Infect Dis 2024;230:e1182-e1201. https://doi.org/10.1093/infdis/jiae314
3. Shi T, Vennard S, Jasiewicz F, et al. Disease burden estimates of respiratory syncytial virus-related acute respiratory infections in adults with comorbidity: a systematic review and meta-analysis. J Infect Dis 2022;226(Suppl 1):S17-S21. https://doi. org/10.1093/infdis/jiab040
4. Savic M, Penders Y, Shi T, et al. Respiratory syncytial virus disease burden in adults aged 60 years and older in high-income countries: a systematic literature review and meta-analysis. Influenza Other Respir Viruses 2023;17:e13031. https://doi. org/10.1111/irv.13031
5. Tseng HF, Sy LS, Ackerson B, et al. Severe morbidity and short- and mid- to long-term mortality in older adults hospitalised with respiratory syncytial virus infection. J Infect Dis 2020;222:1298-1310. https://doi.org/10.1093/infdis/jiaa361
6. Elsobky M, Leite J, Mousa M, et al. Adult respiratory syncytial virus disease burden: systematic literature review in Africa, Asia, Latin America and the Middle East (2010– 2022). Future Virol 2024;19:483-503.
7. Moyes J, Walaza S, Pretorius M, et al. Respiratory syncytial virus in adults with severe acute respiratory illness in a high-prevalence setting. J Infect 2017;75:346-355. https:// doi.org/10.1016/j.jinf.2017.06.007
8. Moyes J, Tempia S, Walaza S, et al. Risk factors for severe respiratory syncytial virus- associated respiratory tract infection in a high HIV-prevalence setting, South Africa, 2012–2018. BMC Infect Dis 2024;24:1128. https://doi.org/10.1186/s12879-024-10024-9
9. Kelleher K, Subramanian N, Drysdale SB. The recent landscape of RSV vaccine research. Ther Adv Vaccines 2025;13:1-19. https://doi.org/10.1177/25151355241310601
10. Papi A, Ison MG, Langley JM, et al. Respiratory syncytial virus prefusion F protein vaccine in older adults. N Engl J Med 2023;388:595-608. https://doi.org/10.1056/ nejmoa2209604
11. Walsh EE, Perez Marc G, Zareba AM, et al. Efficacy and safety of a bivalent RSV prefusion F vaccine in older adults. N Engl J Med 2023;388:1465-1477. https://doi. org/10.1056/nejmoa2213836
12. Kampmann B, Madhi SA, Munjal I, et al. Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants. N Engl J Med 2023;388:1451-1464. https://doi. org/10.1056/nejmc2307729
13. Wilson E, Goswami J, Baqui AH, et al. Efficacy and safety of an mRNA-based RV prefusion F vaccine in older adults. N Engl J Med 2023;389:2233-2244.
14. Government is considering providing a vaccine to protect babies from RSV. Spotlight 2025. https://www.spotlightnsp.co.za/2025/07/15/goverment-is-considering- providing-a-vaccine-to-protect-babies-from-RSV/